MP31-09 THROMBOEMBOLIC RISK WITH THE USE OF TESTOSTERONE THERAPY IN KLINEFELTER SYNDROME

Abstract

You have accessJournal of UrologyInfertility: Therapy (MP31)1 Sep 2021MP31-09 THROMBOEMBOLIC RISK WITH THE USE OF TESTOSTERONE THERAPY IN KLINEFELTER SYNDROME Sophie Birch, Andreas Espehana, Yamini Kailash, Paul Caroll, Awatul El-Shirif, Leila Frodsham, Mona Salman, Paula Allchorne, Fredrick Melling, Charlotte Tomlinson, and Tet Yap Sophie BirchSophie Birch More articles by this author , Andreas EspehanaAndreas Espehana More articles by this author , Yamini KailashYamini Kailash More articles by this author , Paul CarollPaul Caroll More articles by this author , Awatul El-ShirifAwatul El-Shirif More articles by this author , Leila FrodshamLeila Frodsham More articles by this author , Mona SalmanMona Salman More articles by this author , Paula AllchornePaula Allchorne More articles by this author , Fredrick MellingFredrick Melling More articles by this author , Charlotte TomlinsonCharlotte Tomlinson More articles by this author , and Tet YapTet Yap More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002035.09AboutAbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail Abstract INTRODUCTION AND OBJECTIVE: Klinefelter Syndrome (KS) is the most prevalent chromosomal disorder in men, defined by having 1 or more extra X chromosome. Literature suggest that there is an increased risk of thromboembolic events in men with KS, with a cumulative incidence of deep vein thrombosis (DVTs) of 8.6% by the age of 50, though the exact mechanism is not known. Testosterone supplementation therapy (TT) is one of the main treatment for KS patients, and this may further increase their risk of thrombotic event. This study was done to assess the impact of testosterone therapy on the incidence of thromboembolism in KS patients. METHODS: Prospectively collected data from March 2017 to January 2020 across a national-access KS multidisciplinary & endocrine clinics from a large tertiary teaching hospital was analysed. In parallel, a community based survey was carried out with the national Klinefelter Association (KSA). Information on thromboembolism incidence, testosterone supplementation use, and population characteristics was collated to compare outcomes between testosterone-treated and untreated KS patients. Ethics approval was obtained for the study. RESULTS: A total of 235 patients were found from the survey & databases and were included in the study, of which there were 79 patients receiving some form of TT (Treated), and 156 not receiving TT (Untreated). 24 (30.4%) of Treated and 17 (10.9%) Untreated men had at least one thromboembolic event (p<0.001). Within these groups, 7 (8.9%) Treated and 7 (4.5%) Untreated men experienced a recurrence. Deep vein thrombosis (DVT) was the most common form of thromboembolism, accounting for 11 (45.8%) of Treated men, and 4 (23.5%) of Untreated men. The length of TT for Treated men who did experience a thromboembolic event was known for 22 out of 24 (91.7%) men. Men on TT for >24 months prior to 1st thromboembolic event represented the majority (70.8%, n=17) of the Treated group’s thromboembolisms. CONCLUSIONS: This study showed higher incidence of thromboembolic events in KS patients on testosterone therapy compared to untreated groups. Further observational studies will be crucial for understanding the impact of TT in KS and should consider the wide range of environmental factors that may contribute to thromboembolism, as well as specific data testosterone intervention. Source of Funding: none © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e558-e558 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Sophie Birch More articles by this author Andreas Espehana More articles by this author Yamini Kailash More articles by this author Paul Caroll More articles by this author Awatul El-Shirif More articles by this author Leila Frodsham More articles by this author Mona Salman More articles by this author Paula Allchorne More articles by this author Fredrick Melling More articles by this author Charlotte Tomlinson More articles by this author Tet Yap More articles by this author Expand All Advertisement Advertisement Loading ...